UroGen Pharma Ltd. financial data

Symbol
URGN on Nasdaq
Industry
Pharmaceutical Preparations
Location
9 Ha'ta'asiya St, Ra'anana, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 755 % +57.2%
Quick Ratio 22.4 % +15.4%
Debt-to-equity -2.04K % -755%
Return On Equity 932 % +757%
Return On Assets -47.9 % +38.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.2M shares +36.7%
Common Stock, Shares, Outstanding 42.2M shares -0.02%
Entity Public Float 190M USD +31.2%
Common Stock, Value, Issued 115K USD +36.9%
Weighted Average Number of Shares Outstanding, Basic 43.1M shares +33.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 89.4M USD +15.6%
Cost of Revenue 8.7M USD -6.88%
Research and Development Expense 53.6M USD +9.76%
Operating Income (Loss) -83.7M USD -17.6%
Nonoperating Income (Expense) 457K USD -323%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -111M USD -6.71%
Income Tax Expense (Benefit) 4.04M USD +435%
Net Income (Loss) Attributable to Parent -115M USD -9.78%
Earnings Per Share, Basic -2.97 USD/shares +30.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 125M USD +4.7%
Cash, Cash Equivalents, and Short-term Investments 254M USD +65.2%
Accounts Receivable, after Allowance for Credit Loss, Current 22.8M USD +77.5%
Inventory, Net 7.59M USD +51.8%
Assets, Current 295M USD +62%
Property, Plant and Equipment, Net 608K USD -26.1%
Operating Lease, Right-of-Use Asset 1.05M USD -44.8%
Other Assets, Noncurrent 370K USD -82%
Assets 302M USD +55.9%
Accounts Payable, Current 5.56M USD +37.5%
Employee-related Liabilities, Current 9.03M USD +10.8%
Liabilities, Current 32.8M USD +27.1%
Operating Lease, Liability, Noncurrent 212K USD -79.3%
Liabilities 276M USD +17.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 236K USD
Retained Earnings (Accumulated Deficit) -769M USD -17.7%
Stockholders' Equity Attributable to Parent 25.5M USD
Liabilities and Equity 302M USD +55.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.7M USD -23%
Net Cash Provided by (Used in) Financing Activities 54.7M USD +8046%
Net Cash Provided by (Used in) Investing Activities 13.5M USD +116%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 42.2M shares +36.7%
Common Stock, Par or Stated Value Per Share 0.01 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 36.4M USD
Deferred Tax Assets, Valuation Allowance 144M USD +10.8%
Operating Lease, Liability 1.04M USD -45%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -115M USD -9.45%
Lessee, Operating Lease, Liability, to be Paid 1.1M USD -47.4%
Property, Plant and Equipment, Gross 4.82M USD +5.15%
Operating Lease, Liability, Current 825K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 58K USD -92.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 820K USD -11.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 60K USD -70%
Lessee, Operating Lease, Liability, to be Paid, Year Three 58K USD -92.6%
Deferred Tax Assets, Operating Loss Carryforwards 104M USD +7.4%
Unrecognized Tax Benefits 3.2M USD +6.67%
Lessee, Operating Lease, Liability, to be Paid, Year Four 49K USD
Operating Lease, Payments 277K USD -5.78%
Depreciation, Depletion and Amortization 508K USD -45.1%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 12.4M USD +36.4%